Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA5 | P31644 | 1/20 | 0.37 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | DAGLA | Q9Y4D2 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.33 |
| ▸ | FPR3 | P25089 | 1/20 | 0.33 |
| ▸ | FPR2 | P25090 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 2/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25144893 | 0.81 | FPR3 (0.34) | DAGLAFPR3FPR2 | |
| SCHEMBL5281143 | 0.77 | CDK8 (0.40) | GABRA5GABRB2HSD17B10ALDH1A1KDM4E | |
| SCHEMBL17653831 | 0.73 | ALDH1A1 (0.38) | GABRA5GABRB2HSD17B10ALDH1A1KDM4E | |
| SCHEMBL27917207 | 0.72 | GABRA5 (0.42) | GABRA5GABRB2HSD17B10ALDH1A1KDM4E | |
| SCHEMBL15284163 | 0.71 | BACE1 (0.33) | FPR3FPR2HPGDMAPT | |
| SCHEMBL27935881 | 0.71 | ALDH1A1 (0.39) | GABRA5GABRB2HSD17B10ALDH1A1KDM4E | |
| SCHEMBL1807276 | 0.71 | CES1 (0.45) | DAGLAALDH1A1KDM4EALOX15TDP1 | |
| SCHEMBL27545045 | 0.70 | GABRA5 (0.37) | GABRA5GABRB2HSD17B10ALDH1A1KDM4E | |
| SCHEMBL27926971 | 0.70 | GABRA5 (0.37) | GABRA5GABRB2HSD17B10ALDH1A1KDM4E | |
| SCHEMBL754504 | 0.70 | NPSR1 (0.42) | L3MBTL1LMNAHPGDMAPTTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102803237-B | Oxazole and thiazole derivatives as alx receptor agonists | ACTELION PHARMACEUTICALS LTD | 2014-09-24 | — | — | CN | disclosed |
| US-8674111-B2 | Oxazole and thiazole derivatives as ALX receptor agonists | ACTELION PHARMACEUTICALS LTD. (CH) | 2014-03-18 | — | — | US | disclosed |
| EP-2440536-B1 | Oxazole and thiazole derivatives as ALX receptor agonists | ACTELION PHARMACEUTICALS LTD (CH) | 2013-11-06 | — | — | EP | disclosed |
| CN-102803237-A | Oxazole and thiazole derivatives as alx receptor agonists | ACTELION PHARMACEUTICALS LTD | 2012-11-28 | — | — | CN | disclosed |
| US-20120115916-A1 | OXAZOLE AND THIAZOLE DERIVATIVES AS ALX RECEPTOR AGONISTS | ACTELION PHARMACEUTICALS LTD. (CH) | 2012-05-10 | — | — | US | disclosed |
| EP-2440536-A1 | OXAZOLE AND THIAZOLE DERIVATIVES AS ALX RECEPTOR AGONISTS | Actelion Pharmaceuticals Ltd. (CH) | 2012-04-18 | — | — | EP | disclosed |
| WO-2010143158-A1 | OXAZOLE AND THIAZOLE DERIVATIVES AS ALX RECEPTOR AGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2010-12-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120115916-A1 | OXAZOLE AND THIAZOLE DERIVATIVES AS ALX RECEPTOR AGONISTS | P2RX1, GLP1R, P2RX7 | GABRA5 102/4885GABRB2 237/4885HSD17B10 1552/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.